Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot ovarian cancer type before surgery

NCT ID NCT06709872

Diagnosis Sponsor: KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to improve how doctors tell the difference between borderline ovarian tumors and early-stage invasive ovarian cancer before surgery. Researchers will test a panel of nine blood-based biomarkers in 400 women with suspicious ovarian cysts. If successful, this could lead to more accurate diagnoses and better treatment decisions without needing immediate surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with ultrasound discovery of a cyst on the ovary, suspicious for BOT or stage I invasive tumor

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants eligible for inclusion in this study must meet all of the following criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. At least 18 years of age at the time of signing the Informed Consent Form (ICF) 3. Ultrasound discovery of a cyst on the ovary, suspicious for BOT or stage I invasive tumor (subjective assessment) Exclusion Criteria: * Participants eligible for this Study must not meet any of the following criteria: 1. Participants younger than 18 years old, 2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive 3. Participants who refuse the preoperative transvaginal ultrasonography and/or blood sample 4. Participants with known simultaneous and/or previous malignancies within five years prior to BIOC participation 5. Participants with infectious serology (i.e. HIV, Hepatitis B, Hepatitis C) 6. Participants who deny or withdraw the written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline ovarian tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

borderline epithelial tumor of ovary disease ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline ovarian tumors Stage I ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Faculty Hospital of the Charles University

    RECRUITING

    Prague, Czechia

  • Istituto Nazionale dei Tumore

    NOT_YET_RECRUITING

    Milan, Italy

  • UZ Leuven

    RECRUITING

    Leuven, Flemish Brabant, 3000, Belgium

  • Università Cattolica del Sacro Cuore

    NOT_YET_RECRUITING

    Rome, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.